Physician profile
John Cleary
NPI 1285636514
$1,025.66
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $93.07.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $356.78 | 2019-2020 | |
| Glaxosmithkline, LLC. | $248.07 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.44 | 2019 | |
| Genzyme Corporation | $48.53 | 2019 | |
| Gilead Sciences, INC. | $35.97 | 2019 | |
| Genentech USA, INC. | $32.80 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $27.42 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $27.38 | 2019 | |
| Mylan Specialty L.P. | $23.56 | 2019 | |
| Shire North American Group INC | $20.08 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.87 | 2019 | |
| Circassia INC. | $17.42 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.92 | 2019 | |
| Insmed, INC. | $16.45 | 2020 | |
| Fisher & Paykel Healthcare INC | $10.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cleary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.